CNCE Concert Pharmaceuticals Inc.

7.32
-0.09  -1%
Previous Close 7.41
Open 7.44
Price To Book 1.46
Market Cap 174,517,255
Shares 23,841,155
Volume 116,742
Short Ratio
Av. Daily Volume 255,869
Stock charts supplied by TradingView

NewsSee all news

  1. Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

    CTP-692 Offers Potentially New Approach as an Adjunctive Treatment to Improve Overall Symptoms in Patients with Schizophrenia Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the initiation of a Phase 2

  2. Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2019 Healthcare Conference on November 19, 2019 at 1:50 p.m. ET;

  3. Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update

    Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2019. "Over the past several months, we have presented important

  4. Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019.

  5. Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial planned for 2020.
CTP-543
Alopecia areata
Phase 3 trial did not meet primary endpoint - September 27, 2019.
AVP-786
Agitation in patients with Alzheimer's disease
Phase 3 planned. Needs partner
CTP-499
Diabetic Kidney Disease
Phase 2 monotherapy trial initiated 2Q 2019.
VX-561
Cystic fibrosis who have a gating mutation
Phase 2 trial initiation announced December 2, 2019. Data due end of 2020.
CTP-692
Schizophrenia
Phase 2 trial to be completed 4Q 2019.
CTP-543 - open label (Once-Daily vs. Twice-Daily)
Alopecia areata
Phase 2 combo trial initiated May 2019.
VX-561 and VX-121
Cystic Fibrosis
Phase 2 data due 1H 2020.
CTP-543 - open label (12 mg twice-daily or 24 mg once-daily)
Alopecia areata

Latest News

  1. Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophrenia

    CTP-692 Offers Potentially New Approach as an Adjunctive Treatment to Improve Overall Symptoms in Patients with Schizophrenia Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the initiation of a Phase 2

  2. Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the following upcoming investor conferences: The Stifel 2019 Healthcare Conference on November 19, 2019 at 1:50 p.m. ET;

  3. Concert Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Company Update

    Conference Call Scheduled Today at 8:30 a.m. ET Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today reported financial results for the third quarter of 2019. "Over the past several months, we have presented important

  4. Concert Pharmaceuticals to Host KOL Webcast Event Focused on CTP-692 and Schizophrenia

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will host a conference call and webcast event with a key opinion leader in the field of psychiatry and schizophrenia on Thursday, November 14, 2019.

  5. Concert Pharmaceuticals to Report Third Quarter 2019 Financial Results on November 7, 2019

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will report its third quarter 2019 financial results on Thursday, November 7, 2019, before the U.S. financial markets open. The Company will host a

  6. Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today presented results from its recently completed Phase 2 dose-ranging trial of the investigational medicine CTP-543 in patients with moderate-to-severe alopecia areata, an

  7. Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference

    Company developing two proprietary drug candidates based on well‑established biology in alopecia areata and schizophrenia Webcast details for Cantor Healthcare Conference presentation Thursday, October 3, 2019 at 5:20

  8. Concert Pharmaceuticals Names Jeffrey Munsie as Chief Legal Officer

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has named Jeffrey A. Munsie to the position of Chief Legal Officer. In this role, Mr. Munsie will have overall responsibility for key general corporate

  9. Concert Pharmaceuticals Completes Enrollment in Second Open Label Trial of CTP-543 to Evaluate Once-Daily vs. Twice-Daily Dosing in Patients with Alopecia Areata

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in

  10. Concert Pharmaceuticals Announces CTP-543 Phase 2 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2019 EADV Congress

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will present results from its recently completed Phase 2 trial of CTP-543 in patients with moderate-to-severe alopecia areata. These data will be

  11. Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

    CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Advancement into Phase 3 Evaluation Planned in 2020 Company to Host Investor Conference Call Today at 8:30 a.m. ET Concert

  12. Concert Pharmaceuticals Reports Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

    CTP-543 Achieved its Primary Endpoint in the 8 mg and 12 mg Twice-Daily Dosing Cohorts Advancement into Phase 3 Evaluation Planned in 2020 Company to Host Investor Conference Call Today at 8:30 a.m. ET Concert

  13. Concert Pharmaceuticals to Present at Upcoming Investor Conferences

    Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate at the following upcoming investor conferences: The H.C. Wainwright 21st Annual Healthcare Conference on September 9, 2019 at 8:45